OKI-219, a PI3KaH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in preclinical PI3KaH1047R mutant breast cancer models

被引：0
|
作者：
Taylor, Molly A.
Zhao, Qian
Mareska, David
Hoh, Maria
Izrayelit, Yevgeniy
Litwiler, Kevin
Boys, Mark L.
Woessner, Rich
Walker, Duncan
Winkler, James D.
Diamond, Jennifer
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-25-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-25-09
引用
收藏
页数：3
相关论文
共 15 条
  • [1] Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Kα
    Taylor, Molly A.
    Zhao, Qian
    Mareska, David
    Hoh, Maria
    Izrayelit, Yevgeniy
    Litwiler, Kevin
    Boys, Mark L.
    Woessner, Rich
    Walker, Duncan
    Diamond, Jennifer
    Winkler, James D.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models
    Puca, Loredana
    Dowless, Michele S.
    Perez-Ferreiro, Carmen M.
    Ortiz-Ruiz, Maria Jesus
    Donoho, Gregory P.
    Capen, Andrew
    Huber, Lysiane
    Bogner, Sarah M.
    Fei, Dongling
    Manro, Jason R.
    Yu, Chun Ping
    Xu, Wei Guo
    Wang, Rui
    Chen, Shuang
    Hicks, Mark A.
    Zolfaghari, Parisa
    Faber, Andrew
    Gilmour, Raymond
    Ramstetter, Monica D.
    Chang, Matthew T.
    Lallena, Maria Jose
    Gong, Xuequian
    Hyman, David M.
    Smyth, Lillian M.
    Brandhuber, Barbara J.
    Taylor, Barry S.
    Klippel, Anke
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [3] OKI-219 is an inhibitor of PI3K α H1047R that has brain penetrance and anti-tumor activity in a preclinical intracranial model of metastatic breast cancer
    Strait, Alexander A.
    Taylor, Molly A.
    Litwiler, Kevin S.
    Zhao, Qian
    Mareska, David A.
    Boys, Mark L.
    Izrayelit, Yevgeniy
    Woessner, Richard
    Winkler, James D.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [4] GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
    Hong, Rebecca
    Edgar, Kyle
    Song, Kyung
    Steven, Schmidt
    Young, Amy
    Hamilton, Patricia
    Arrazate, Alfonso
    De La Cruz, Cecile
    Chan, Connie
    Pang, Jodie
    Salphati, Laurent
    Belvin, Marcia
    Nannini, Michelle
    Staben, Steven
    Friedman, Lori
    Sampath, Deepak
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [5] RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
    Pazolli, Ermira
    Kipp, Randy
    Boezio, Alessandro
    Gunaydin, Hakan
    Iskandar, Amanda
    Zubrowski, Matthew
    Williams, Bret
    Shortsleeves, Kelley
    Larivee, Alexandre
    McLean, Tom
    Michelsen, Klaus
    Zeng, Hongtao
    LaRochelle, Jonathan
    Manna, Joe
    DiPietro, Lucian
    Lescarbeau, Andre
    Mader, Mary
    Bennet, Bindu
    Wilbur, Jeremy
    Wang, Qi
    Pierce, Levi
    Martin, Iain
    Watters, James
    Fortin, Pascal
    Bergstrom, Donald
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [6] Preclinical in vitro and in vivo characterization of a novel, wild-type-sparing, PI3Ka H1047R mutant-selective inhibitor
    Smith, Aaron C.
    Arwood-Levine, Ben
    Born, Alexandra
    Brizendine, Richard
    Chatterjee, Payal
    Chicarelli, Mark J.
    Conner, Michael L.
    Fell, Brad
    Fulton, Jennifer
    Guarnieri, Anna
    Jalluri, Ravi
    Knox, Hailey
    Koch, Keith
    Krischlunas, Daniel
    Kumar, Vijay
    McHugh, Colin
    Mclean, Brent
    Nassar, Kelsey
    Newhouse, Brad
    Rieger, Rob
    Robinson, John
    Rodriguez, Mareli
    Salituro, Leah
    Stunkard, Lee
    Sullivan, Francis
    Turton, Roy
    Winski, Shannon
    Zhou, Yeyun
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [7] Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
    Klippel, Anke
    Wang, Rui
    Puca, Loredana
    Faber, Andrew Lee
    Shen, Weihua
    Bhagwat, Shripad V.
    Karukurichi, Kannan
    Zhang, Feiyu Fred
    Perez, Carmen
    Rama, Ramon
    Ramos, Ana
    Zheng, Yi
    Bonday, Zahid
    Thomas, James
    Brooks, Harold B.
    Kindler, Lisa J.
    Bogner, Sarah M.
    Zolfaghari, Parisa
    Hicks, Mark, II
    Callies, Sophie
    Mattioni, Brian
    LeBrun, Laurie
    Durbin, Jim
    Anderson, Erin
    Mayne, Chris
    Kesicki, Edward
    Kolakowski, Gabrielle
    Andrews, Steven W.
    Brandhuber, Barbara J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [8] The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models
    Sampath, D.
    Nannini, M. A.
    Jane, G.
    Hong, R.
    Parsons, K. L.
    Belvin, M.
    Friedman, L. S.
    Wallin, J. J.
    [J]. CANCER RESEARCH, 2013, 73
  • [9] A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)
    Juric, Dejan
    Jhaveri, Komal
    Beeram, Muralidhar
    Hamilton, Erika
    Chau, Vincent
    Hanley, Matthew P.
    Liu, Shiyao
    Smyth, Lillian M.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [10] Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models
    Fritsch, Christine
    Pfister, Estelle
    Ebel, Nicolas
    Guthy, Daniel
    Schnell, Christian
    Hofmann, Francesco
    [J]. CANCER RESEARCH, 2018, 78 (13)
12